FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2019/12/022577 [Registered on: 31/12/2019] Trial Registered Prospectively
Last Modified On: 04/12/2019
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Diagnostic 
Study Design  Single Arm Study 
Public Title of Study   Nuclear and cytological abnormalities in scrap cytology in patients with pre and early malignant lesions or oral cavity and oropharynx  
Scientific Title of Study   Cytomorphological features of presence and number of AgNOR avid regions and micronuclear score compared to CK-8 immunoreactive controls in premalignant and early malignant lesions of oral cavity and oropharynx 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Sourabha Kumar Patro 
Designation  Assistant Professor 
Affiliation  AIIMS, Jodhpur 
Address  DEPT OF ENT 408 ENT OPD A BLOCK 4TH FLOOR AIIMS BASNI Jodhpur rajasthan

Jodhpur
RAJASTHAN
342005
India 
Phone  8360843906  
Fax  91-291-2740531  
Email  sourabhlipi@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Sourabha Kumar Patro 
Designation  Assistant Professor 
Affiliation  AIIMS, Jodhpur 
Address  DEPT OF ENT 408 ENT OPD A BLOCK 4TH FLOOR AIIMS BASNI Jodhpur rajasthan

Jodhpur
RAJASTHAN
342005
India 
Phone  8360843906  
Fax  91-291-2740531  
Email  sourabhlipi@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Darwin  
Designation  Assistant Professor 
Affiliation  AIIMS, Jodhpur 
Address  DEPT OF ENT 408 ENT OPD A BLOCK 4TH FLOOR AIIMS BASNI Jodhpur rajasthan

Jodhpur
RAJASTHAN
342005
India 
Phone  8003647999  
Fax  91-291-2740531  
Email  drdarwin.aiims@gmail.com  
 
Source of Monetary or Material Support  
AIIMS Jodhpur intramural research fund amount sanctioned: 2,69,063 
 
Primary Sponsor  
Name  AIIMS Jodhpur 
Address  AIIMS BASNI Jodhpur 342005 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 2  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Darwin  AIIMS, Jodhpur  AIIMS, BASNI, JODHPUR
Jodhpur
RAJASTHAN 
00918003647999

drdarwin.aiims@gmail.com 
Dr Sourabha Kumar Patro  AIIMS, Jodhpur  AIIMS, BASNI, Jodhpur
Jodhpur
RAJASTHAN 
00918872401912

sourabhlipi@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institute ethics committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C00-C14||Malignant neoplasms of lip, oral cavity and pharynx, (2) ICD-10 Condition: D10||Benign neoplasm of mouth and pharynx, (3) ICD-10 Condition: D498||Neoplasm of unspecified behavior of other specified sites,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Biopsy procedure and histopathological grading   Cytological preparation and evaluation   Biopsy procedure and histopathological grading Incisional biopsies will be taken from the representative sites with all aseptic precautions. The tissue specimen will be labelled, fixed in 10% neutral buffered formalin for 24 h, and paraffin embedded. The wax blocks will be cut to obtain two tissue sections of 4-5 μm thickness for each block and the sections will be stained by haematoxylin and eosin. Immunohistochemistry (CK8) will be performed on relevant cases.   Cytological preparation and evaluation Subjects will be asked to rinse their mouth gently with tap water. To obtain the smear of exfoliated cells from the oral cavity (buccal mucosa in control group), a slightly moistened wooden spatula will be used. For pre malignant lesions representative site selected will be areas of leucoplakia, erythroplakia & oral sub mucous fibrosis in oral cavity and oropharynx. In OSCC patients, oral mucosal cells will be scraped from the margins of the lesion for obtaining the smear. The cells will be immediately smeared on pre cleaned microscopic slides. Just prior to drying, the smears will be fixed with commercially available spray fixative for 15 min. The slides will be labelled and preserved in dust-free boxes until evaluation. Biopsy & histopathological examination will be carried out in relevant cases based upon cytopathological findingThe smears will be stained by Papanicolaou technique using a commercially available staining kit RAPIDPAP, Feulgen stain, AgNOR stain & acridine orange. From each slide, 500 cells will be examined under the light microscope using low magnification (×400) for screening and high magnification (×1000) for counting of MN. Scoring criteria The criteria which was developed by Tolbert et al. was used for counting the MN. Screening of each slide was made in a zigzag manner from one end, toward the other end of the slide. Tolbert et al. criteria parameters for identifying MN are as follows: Only those structures fulfilling the above-mentioned criteria were recorded as MN. For Silver avid regions we intend to calculate number of Ag avid regions and its presence of absence. The nuclear features and dimensions will be recorded using the standard software available for calculating nuclear dimensions. Inclusion and exclusion criteria (Post-cytology) Micronucleated cells will be counted out of 500 intact epithelial cells, and they were expressed as percentages. Nuclear blebbing (MN-like structure connected with the main nucleus with a bridge) are not considered. Clumps of cells with obscured nuclear or cytoplasmic boundaries and overlapping of cells are avoided and separated or cells lying singly are preferred for counting of MN. Dead or degenerated cells, apoptotic cells, and cytoplasmic fragments are excluded from evaluation.  
Comparator Agent  Histopathology  Routine Histopathology done for diagnosis through biopsies 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  85.00 Year(s)
Gender  Both 
Details  Patients of premalignant and early malignant oral and oropharyngeal lesions 
 
ExclusionCriteria 
Details  Patients with known mutation diagnosed tumour syndromes of pre confirmed familial cancer syndromes will be excluded as their molecular progression is already established. Patients not consenting for the study will also be excluded.  
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
We expect to find some differential expression of nuclear and micronuclear features such as shape and pattern of nucleus, nuclear staining features, presence and number of AgNOR avid regions and presence, CK-8 immuno-reactivity and number of micronucleus scores in various stages of premalignant and early malignant oral and oropharyngeal lesions which can be further analysed for studying its clinical implications.   0 to 6 months
1 Sample collection
2 Procurement of stains antibodies and detection kit

7 to 18 months
1 Standardization of the staining and IHC protocol
2 Prospective case analysis by staining and IHC
19 to 24 months Compilation of data and submission along with knowledge outcome in terms of a paper
 
 
Secondary Outcome  
Outcome  TimePoints 
A cyto morphological score with a cut off value for malignant changes   at 24 months during final analysis 
 
Target Sample Size   Total Sample Size="160"
Sample Size from India="160" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   01/01/2020 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   We expect around 2 to 3 scientific publications from the study 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  

India shares a major burden of oral and oropharyngeal cancers of the world. 1 Even with the major advances in the surgical techniques and nonsurgical modalities such as various forms of radiotherapy, chemotherapy and targeted therapy, overall outcome in terms of 5 year survival remains at 56% in oral and oropharyngeal cancers.2 The prognosis is still worse in Indian patients  with high incidences of p53 mutations.3 Delay in detection of these cases is one of the prime reason for such outcomes. Cancers at other sites such as cervix and breast do have better outcomes due to routine screening of early stage lesions which are detected early of any developing malignant changes in the lesion. Similar results of improved survivals are anticipated in a scenario of detectable cyto-morphological changes that can be easily detected and prognosticated4,5. This will help in detecting the malignancies at an early stage, will reduce the overall disease burden and will improve the overall treatment outcome of oral and oropharyngeal cancers.

Nuclear and cytological markers of developing neoplastic transformations includes morphological features including increased nuclear cytoplasmic ratios, increased nuclear diameter and decreased cellular diameters; featured of proliferative activity such as increased number of regions with affinity for silver stains (AgNOR) and percentage of cells with >3 AgNOR avid regions; and meta nuclear alterations including increased number of micronuclei, cells with karyorrhexis and bi-nucleated cells. Micronucleus is a marker of chromosomal damage, genome instability and carcinogenesis, integrating acquired mutations and genetic susceptibility towards mutations.6,7 Possible role of identification of such cytological nuclear features has been proven in buccal cells in literature to identify DNA damage8 and  in cases of buccal cancer4. However, there is still lack of literature about its diagnostic and prognostic significance in premalignant lesions where these can act as indicators of DNA damage and carcinogenesis for early detection of developing malignancies. The prognostic significance of cyto-morphologic nuclear and micro-nuclear changes in oral premalignant lesions is also needed to be established.

 

Hence we plan to conduct this study in order to see for various cytomorphologic and nuclear changes in oral and oropharyngeal premalignant and malignant lesions, to establish its diagnostic significance for early diagnosis and management in premalignant lesions in developing malignancies and prognostic significance in early malignant lesions of oral cavity and oropharynx.

Methods:

The various method for studying these nuclear and micro nuclear changes includes molecular biologic techniques such as flow cytometry, FISH, routine stains, DNA specific stains, Fluorescent stains and immune stains. Nonspecific routine stains include Giemsa, H & E, Crystal violet, Azan and Papanicolaou etc. DNA specific stains include diamine phenylindole (DAPI), Hoechst 33528, Ethidium Iodide/Bromide, Acridine Orange and Propidium Iodide etc. Automation is possible in diamine phenylindole (DAPI), Hoechst 33528, Ethidium Iodide/Bromide and Propidium Iodide. We intend to include Acridine orange, Fuelgen, Papanicolaou, AgNOR and CK-8 antibodies in cell blocks or standard histopathologic examinations of the identified patients for our analysis.

Post recruitment and consent patients will be taken for definitive diagnosis and management as per the routine departmental protocols and send for scrap cytology. The smears hence collected will be Collection of exfoliated cells. Subjects will be asked to rinse their mouth gently with tap water. To obtain the smear of exfoliated cells from the oral cavity (buccal mucosa in control group), a slightly moistened wooden spatula will be used. For pre malignant lesions representative site selected will be areas of leucoplakia, erythroplakia & oral sub mucous fibrosis in oral cavity and oropharynx. In OSCC patients, oral mucosal cells will be scraped from the margins of the lesion for obtaining the smear. The cells will be immediately smeared on pre cleaned microscopic slides. Just prior to drying, the smears will be fixed with commercially available spray fixative for 15 min. The slides will be labelled and preserved in dust-free boxes until evaluation. Biopsy & histopathological examination will be carried out in relevant cases based upon cytopathological findings.

Biopsy procedure and histopathological grading

Incisional biopsies will be taken from the representative sites with all aseptic precautions. The tissue specimen will be labelled, fixed in 10% neutral buffered formalin for 24 h, and paraffin embedded. The wax blocks will be cut to obtain two tissue sections of 4-5 μm thickness for each block and the sections will be stained by haematoxylin and eosin. Immunohistochemistry (CK8) will be performed on relevant cases.


 

Cytological preparation and evaluation

The smears will be stained by Papanicolaou technique using a commercially available staining kit RAPIDPAP, Feulgen stain, AgNOR stain & acridine orange. From each slide, 500 cells will be examined under the light microscope using low magnification (×400) for screening and high magnification (×1000) for counting of MN.

 

Scoring criteria

The criteria which was developed by Tolbert et al. was used for counting the MN. Screening of each slide was made in a zigzag manner from one end, toward the other end of the slide.

Tolbert et al. criteria parameters for identifying MN are as follows:

1.      Rounded smooth perimeter suggestive of a membrane.

2.      Less than a third the diameter of associated nucleus, but large enough to discern shape and colour.

3.      Staining intensity similar to nucleus.

4.      Same focal plane as nucleus.

5.      Texture similar to nucleus.

6.      The absence of overlap with or bridge to the nucleus.

Only those structures fulfilling the above-mentioned criteria were recorded as MN.

            For Silver avid regions we intend to calculate number of Ag avid regions and its presence of absence.

            The nuclear features and dimensions will be recorded using the standard software available for calculating nuclear dimensions.

Inclusion and exclusion criteria (Post-cytology)

Micronucleated cells will be counted out of 500 intact epithelial cells, and they were expressed as percentages. Nuclear blebbing (MN-like structure connected with the main nucleus with a bridge) are not considered. Clumps of cells with obscured nuclear or cytoplasmic boundaries and overlapping of cells are avoided and separated or cells lying singly are preferred for counting of MN. Dead or degenerated cells, apoptotic cells, and cytoplasmic fragments are excluded from evaluation.

Mile stone

Targets

0-6 months

1.      Sample collection.

2.      Procurement of stains, antibodies and detection kit.

 

7-18 months

1.      Standardization of the staining & IHC protocol

2.      Prospective case analysis by staining & IHC

19-24 months

Compilation of data and submission along with knowledge outcome in terms of a paper.

 

 

Data analysis plan

As per the requirement relevant statistical data analysis will be performed using

Independent Samples Test (Student t test)/ chi square for comparison, Pearson’s and spearman’s coefficients for correlation, multiple logistic regressions and ANNOVA of one way, Friedman and kruswal wallis type as desired by the type of the data and situation for multiple groups will be used.

At the end a ROC curve will be plot for the final scores to determine a threshold above which a definite biopsy and referral can be planned for such lesions.  


 



 
Close